Gynecologic Oncology

Journal

Publication Venue For

  • Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study.  158:562-569. 2020
  • Risk of second primary cancers among survivors of gynecological cancers.  158:719-726. 2020
  • Human papillomavirus: The other invisible enemy.  158:254-255. 2020
  • When to Operate, Hesitate and Reintegrate: Society of Gynecologic Oncology Surgical Considerations during the COVID-19 Pandemic.  158:236-243. 2020
  • Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis.  158:16-24. 2020
  • Cardiometabolic comorbidities and epithelial ovarian cancer risk among African-American women in the African-American Cancer Epidemiology Study (AACES).  158:123-129. 2020
  • Patient reported outcomes measures in gynecologic oncology: A primer for clinical use, Part II.  158:201-207. 2020
  • Patient reported outcomes measures in gynecologic oncology: A primer for clinical use, part I.  158:194-200. 2020
  • Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect.  157:578-584. 2020
  • Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancer.  157:765-774. 2020
  • Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002).  157:161-166. 2020
  • The Society of Gynecologic Oncology wellness curriculum pilot: A groundbreaking initiative for fellowship training.  156:710-714. 2020
  • EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer.  156:301-307. 2020
  • Extensive financial hardship among gynecologic cancer patients starting a new line of therapy.  156:271-277. 2020
  • Human papillomavirus vaccination: Ongoing challenges and future directions.  156:498-502. 2020
  • Reducing emergency department (ED) computed tomography (CT) utilization in women treated for gynecologic cancers.  156:288-292. 2020
  • Corrigendum to ‘Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancer’ [Gynecologic Oncology 157 (2020) 765–774] (Gynecologic Oncology (2020) 157(3) (765–774), (S0090825820302262), (10.1016/j.ygyno.2020.03.010)) 2020
  • Extending the platinum-free interval: The impact of omitting 2nd line platinum chemotherapy in intermediate platinum-sensitive ovarian cancer.  155:201-206. 2019
  • Advanced communication: A critical component of high quality gynecologic cancer care: A Society of Gynecologic Oncology evidence based review and guide.  155:161-169. 2019
  • Corrigendum to “Financial toxicity – An overlooked side effect” (Gynecologic Oncology (2018) 150(1) (3–6), (S0090825818308990), (10.1016/j.ygyno.2018.05.012)).  154:449. 2019
  • Differences in referral patterns based on race for women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment Clinic.  154:379-382. 2019
  • Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population.  154:110-117. 2019
  • Gynecologic oncology providers endorse practice-changing impact of communication skills training.  153:633-638. 2019
  • The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up.  153:521-529. 2019
  • Comparative outcomes between robotic and abdominal radical hysterectomy for IB1 cervical cancer: Results from a single high volume institution.  153:242-247. 2019
  • Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer.  152:445-451. 2019
  • The cost-effectiveness of opportunistic salpingectomy versus standard tubal ligation at the time of cesarean delivery for ovarian cancer risk reduction.  152:127-132. 2019
  • Time to chemotherapy in ovarian cancer: Compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer Center..  151:501-505. 2018
  • Impact of enhanced recovery after surgery (ERAS) protocol on gastrointestinal function in gynecologic oncology patients undergoing laparotomy.  151:282-286. 2018
  • Hyperthermic intraperitoneal chemotherapy (HIPEC) is cost-effective in the management of primary ovarian cancer..  151:4-5. 2018
  • Treatment of low-grade endometrial stromal sarcoma in a nulligravid woman.  151:6-9. 2018
  • Disparities in receipt of follow-up care instructions among female adult cancer survivors: Results from a national survey.  150:494-500. 2018
  • Endometrial cancer: Molecular markers and management of advanced stage disease.  150:569-580. 2018
  • Twenty-first century cervical cancer management: A historical perspective of the gynecologic oncology group/NRG oncology over the past twenty years.  150:391-397. 2018
  • Financial toxicity – An overlooked side effect.  150:3-6. 2018
  • Black mother's intention to vaccinate daughters against HPV: A mixed methods approach to identify opportunities for targeted communication.  149:506-512. 2018
  • Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study.  149:525-530. 2018
  • Characteristics of African American women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment Clinic.  149:337-340. 2018
  • Do differences in medical comorbidities and treatment impact racial disparities in epithelial ovarian cancer?.  149:49-52. 2018
  • HPV vaccination.  148:3-4. 2018
  • Values and worries of ovarian cancer patients.  147:433-438. 2017
  • Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study.  147:98-103. 2017
  • The impact of physician burnout on clinical and academic productivity of gynecologic oncologists: A decision analysis.  146:642-646. 2017
  • A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study.  145:291-297. 2017
  • Three versus six cycles of adjuvant platinum-based chemotherapy in early stage clear cell ovarian carcinoma – A multi-institutional cohort.  144:274-278. 2017
  • Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174?.  144:125-129. 2017
  • Effectiveness of cyanoacrylate microbial sealant in the reduction of surgical site infection in gynecologic oncology procedures: A phase III single institution prospective randomized trial.  144:193-199. 2017
  • Early warning score: An indicator of adverse outcomes in postoperative patients on a gynecologic oncology service.  143:105-108. 2016
  • Ovarian cancer and the immune system — The role of targeted therapies.  142:349-356. 2016
  • Improved outcomes with dose-dense paclitaxel-based neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma.  142:25-29. 2016
  • A common clinical dilemma: Management of abnormal vaginal cytology and human papillomavirus test results.  141:364-370. 2016
  • A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16 + cervical intraepithelial neoplasia 2/3 (CIN2/3).  140:245-252. 2016
  • Distance from a Comprehensive Cancer Center: A proxy for poor cervical cancer outcomes?.  143:617-621. 2016
  • Metabolic risk factors and mechanisms of disease in epithelial ovarian cancer: A review.  143:674-683. 2016
  • The role of racial genetic admixture with endometrial cancer outcomes: An NRG Oncology/Gynecologic Oncology Group study.  140:264-269. 2016
  • Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients.  139:413-418. 2015
  • PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: A cost-effectiveness analysis.  139:59-62. 2015
  • Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma.  138:656-662. 2015
  • Setting the bar: compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer Center..  138:689-693. 2015
  • A cost-utility analysis of NRG Oncology/Gynecologic Oncology Group Protocol 218: Incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer.  136:293-299. 2015
  • Use of primary high-risk human papillomavirus testing for cervical cancer screening: Interim clinical guidance.  136:178-182. 2015
  • Bevacizumab in recurrent, persistent, or advanced stage carcinoma of the cervix: Is it cost-effective?.  136:43-47. 2015
  • Evaluation of in vitro chemoresponse profiles in women with Type i and Type II epithelial ovarian cancers: An observational study ancillary analysis.  138:267-271. 2015
  • Ovarian and cervical cancer patient derived xenografts: The past, present, and future.  138:486-491. 2015
  • Prevalence of high-risk human papilloma virus genotypes and associated risk of cervical precancerous lesions in a large U.S. screening population: Data from the ATHENA trial.  137:47-54. 2015
  • Functional variants in CYP1A1 and GSTM1 are associated with clearance of cervical HPV infection.  135:560-564. 2014
  • Teaching gynecologic oncology in Low resource settings: A collaboration of health volunteers overseas and the society of gynecologic oncology.  135:580-582. 2014
  • Validation of a venous thromboembolism risk assessment model in gynecologic oncology..  134:160-163. 2014
  • A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: A Gynecologic Oncology Group study.  133:433-438. 2014
  • A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy.  132:531-536. 2014
  • An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer.  134:331-337. 2014
  • Black race independently predicts worse survival in uterine carcinosarcoma.  133:238-241. 2014
  • Compliance rates and outcomes associated with a restrictive transfusion policy in gynecologic oncology patients.  132:227-230. 2014
  • Diabetes mellitus and ovarian cancer: More complex than just increasing risk.  135:273-277. 2014
  • Inhibition of Wnt/β-catenin pathway by niclosamide: A therapeutic target for ovarian cancer.  134:112-120. 2014
  • Monoclonal antibody-based immunotherapy of ovarian cancer: Targeting ovarian cancer cells with the B7-H3-specific mAb 376.96.  132:203-210. 2014
  • Radical surgical cytoreduction in the treatment of ovarian carcinosarcoma.  133:234-237. 2014
  • Reasons for failure to deliver National Comprehensive Cancer Network (NCCN)-adherent care in the treatment of epithelial ovarian cancer at an NCCN cancer center.  133:142-146. 2014
  • Reducing readmissions after robotic surgical management of endometrial cancer: a potential for improved quality care..  131:508-511. 2013
  • The Wnt/β-catenin pathway in ovarian cancer: A review.  131:772-779. 2013
  • Erratum: HPV vaccination in women treated for CIN2/3: It's still all about prevention (Gynecologic Oncology (2013) 130 (255-256)).  131:499. 2013
  • Folate and folate receptor alpha antagonists mechanism of action in ovarian cancer.  131:493-498. 2013
  • A phase i clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer.  130:518-524. 2013
  • Cost analysis of colposcopy for abnormal cytology in post-treatment surveillance for cervical cancer.  130:421-425. 2013
  • Is the progression free survival advantage of concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin in patients with advanced cervical cancer worth the additional cost? A cost-effectiveness analysis.  130:416-420. 2013
  • Are supportive care-based treatment strategies preferable to standard chemotherapy in recurrent cervical cancer?.  130:317-322. 2013
  • HPV vaccination in women treated for CIN2/3: It's still all about prevention.  130:255-256. 2013
  • Low yield of residual vulvar carcinoma and dysplasia upon re-excision for close or positive margins.  129:528-532. 2013
  • Chemotherapy for advanced and recurrent cervical carcinoma: Results from cooperative group trials.  129:251-257. 2013
  • The endoplasmic reticulum stress marker, glucose-regulated protein-78 (GRP78) in visceral adipocytes predicts endometrial cancer progression and patient survival.  128:552-559. 2013
  • Incidence of port site hernias and/or dehiscence in robotic-assisted procedures in gynecologic oncology patients.  131:123-126. 2013
  • Pre-operative imaging with CA125 is a poor predictor for granulosa cell tumors.  131:59-62. 2013
  • Surgical outcomes and national comprehensive cancer network compliance in advanced ovarian cancer surgery in a low volume military treatment facility.  131:158-162. 2013
  • Re: "The utilization of palliative care in gynecologic oncology patients near the end of life"..  127:678-679. 2012
  • A review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancer.  127:420-425. 2012
  • Cost effectiveness of concurrent gemcitabine and cisplatin with radiation followed by adjuvant gemcitabine and cisplatin in patients with stages IIB to IVA carcinoma of the cervix..  127:267-272. 2012
  • The utilization of palliative care in gynecologic oncology patients near the end of life..  127:175-179. 2012
  • Management of complex pelvic masses using a multivariate index assay: A decision analysis.  126:364-368. 2012
  • Completed versus aborted radical hysterectomy for node-positive stage IB cervical cancer in the modern era of chemoradiation therapy.  126:69-72. 2012
  • Outcomes of patients with gynecologic malignancies undergoing video-assisted thoracoscopic surgery (VATS) and pleurodesis for malignant pleural effusion.  125:646-648. 2012
  • The impact of novel retinoids in combination with platinum chemotherapy on ovarian cancer stem cells.  125:226-230. 2012
  • Does economic burden influence quality of life in breast cancer survivors?.  124:437-443. 2012
  • Targeted inhibition of telomerase activity combined with chemotherapy demonstrates synergy in eliminating ovarian cancer spheroid-forming cells.  124:598-605. 2012
  • Evaluation of the Patient-Generated Subjective Global Assessment (PG-SGA) as a predictor of febrile neutropenia in gynecologic cancer patients receiving combination chemotherapy: a pilot study..  123:360-364. 2011
  • Incidence of mechanical malfunction in low-profile subcutaneous implantable venous access devices in patients receiving chemotherapy for gynecologic malignancies.  123:54-57. 2011
  • A cohort study evaluating robotic versus laparotomy surgical outcomes of obese women with endometrial carcinoma.  122:604-607. 2011
  • Incidence of subsequent abnormal cytology in cervical cancer patients completing five-years of post treatment surveillance without evidence of recurrence..  122:501-504. 2011
  • Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer.  122:532-535. 2011
  • Xanthohumol decreases Notch1 expression and cell growth by cell cycle arrest and induction of apoptosis in epithelial ovarian cancer cell lines.  122:396-401. 2011
  • Multiple synchronous primary ovarian malignancies in a patient with a MLH-1 mutation: Impact on potential fertility preservation..  121:637-638. 2011
  • Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer model.  121:193-199. 2011
  • Cost-effectiveness of using human papillomavirus 16/18 genotype triage in cervical cancer screening.  119:237-242. 2010
  • Long-term outcome and natural history of uterine adenosarcomas.  119:305-308. 2010
  • Overcoming TRAIL resistance in ovarian carcinoma.  119:157-163. 2010
  • Hospice enrollment for terminally ill patients with gynecologic malignancies: impact on outcomes and interventions..  118:274-277. 2010
  • Overcoming the barriers to HPV vaccination in high-risk populations in the US.  117:486-490. 2010
  • What is the role of HPV typing in the United States now and in the next five years in a vaccinated population?.  117:481-485. 2010
  • Efficacy and safety of imatinib mesylate (Gleevec®) and immunohistochemical expression of c-Kit and PDGFR-β in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus.  117:248-254. 2010
  • Epithelioid trophoblastic tumor masquerading as invasive squamous cell carcinoma of the cervix after an ectopic pregnancy..  117:387-388. 2010
  • How does public policy impact cervical screening and vaccination strategies?.  119:175-180. 2010
  • Extragenital adenosarcoma: A case report, review of the literature, and management discussion.  115:472-475. 2009
  • An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC).  115:244-248. 2009
  • The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: a retrospective cohort study..  114:424-426. 2009
  • The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer.  114:242-245. 2009
  • Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer.  113:384-390. 2009
  • Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes.  112:558-562. 2009
  • The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies..  112:601-604. 2009
  • The effect of obesity on survival in patients with ovarian cancer.  112:389-393. 2009
  • A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous Å6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer.  111:89-94. 2008
  • Corrigendum to "The current and future role of screening in the era of HPV vaccination" [Gynecol. Oncol. 109 (2008) S31-S39] (DOI:10.1016/j.ygyno.2008.02.001).  110:270. 2008
  • Panniculectomy concurrent with anterior pelvic exenteration for recurrent cervical cancer.  110:268-269. 2008
  • Age considerations when vaccinating against HPV.  109. 2008
  • Initial lessons learned in HPV vaccination.  109. 2008
  • The disparity of cervical cancer in diverse populations.  109. 2008
  • The future of vaccines for cervical cancer.  109. 2008
  • Anti-tumor activity of the TRA-8 anti-DR5 antibody in combination with cisplatin in an ex vivo human cervical cancer model.  108:591-597. 2008
  • Oncolytic adenovirus Ad5/3-Δ24 and chemotherapy for treatment of orthotopic ovarian cancer.  108:166-172. 2008
  • The current and future role of screening in the era of HPV vaccination.  109. 2008
  • Serous fallopian tube carcinoma: A retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovary.  107:398-403. 2007
  • Primitive neuroectodermal tumor of the myometrium with cardio-vascular symptoms.  106:622-625. 2007
  • Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its therapeutic potential in breast and gynecologic cancers.  106:614-621. 2007
  • Complete uterine necrosis following chemoradiation for advanced cervical cancer: a case report..  106:265-267. 2007
  • A multi-institutional review of outcomes of endometrial stromal sarcoma.  105:630-634. 2007
  • Fertility-sparing radical abdominal trachelectomy for clear cell adenocarcinoma of the upper vagina: A case report.  105:820-822. 2007
  • Anemia correction in malignancy management: Threat or opportunity?.  105:517-529. 2007
  • Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model.  105:291-298. 2007
  • A cost-effectiveness analysis of chemotherapy for patients with recurrent platinum-sensitive epithelial ovarian cancer.  105:223-227. 2007
  • A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapy.  104:591-595. 2007
  • Primary appendiceal cancer: Gynecologic manifestations and treatment options.  104:602-606. 2007
  • Fertility sparing therapy in a patient with placental site trophoblastic tumor: A case report.  103:1141-1143. 2006
  • Recurrence of endometrial adenocarcinoma in a prior Bartholin's cyst marsupialization incision.  103:749-751. 2006
  • Unilateral cervical cancer in a patient with cervix duplex.  103:346-348. 2006
  • Efficacy and toxicity of the novel chemotherapeutic agent KW-2170 in recurrent epithelial ovarian cancer.  102:338-342. 2006
  • Recurrent basosquamous cell carcinoma of the vulva.  102:400-402. 2006
  • Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model.  101:46-54. 2006
  • Carcinosarcoma of the ovary - A case series.  100:128-132. 2006
  • Re: "outcomes of stage I/II vulvar cancer patients after negative superficial inguinal lymphadenectomy" [2] (multiple letters).  100:219-220. 2006
  • Optical detection of cervical neoplasia: results from an internally-controlled multicenter study..  99:S53. 2005
  • The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC).  99:557-563. 2005
  • The use of adjuvant radiation therapy in patients with intermediate-risk Stages IC and II uterine corpus cancer: A patient care evaluation study from the American College of Surgeons National Cancer Data Base.  99:530-535. 2005
  • A comparison of hand-assisted laparoscopy and conventional laparotomy for the surgical evaluation of pelvic masses.  99:443-446. 2005
  • Predictors of outcomes for women with cervical carcinoma.  99:432-436. 2005
  • Feasibility of performing chemoprevention trials in women at elevated risk of ovarian carcinoma: Initial examination of celecoxib as a chemopreventive agent.  98:376-382. 2005
  • Two cases of non-Hodgkin's lymphoma presenting as primary gynecologic malignancies..  98:490-492. 2005
  • Gamma mode of infiltration associated with poor prognosis in malignant teratoma of the ovary: A case report.  98:155-157. 2005
  • Adenoviruses with an RGD-4C modification of the fiber knob elicit a neutralizing antibody response but continue to allow enhanced gene delivery.  96:341-348. 2005
  • Immune responses to human papillomavirus in genital tract of women with cervical cancer.  96:452-461. 2005
  • A case report of rhabdomyosarcoma of the uterus associated with uterine inversion.  96:850-853. 2005
  • Management strategies for stage IB2 cervical cancer: A cost-effectiveness analysis.  97:387-394. 2005
  • Occult choriocarcinoma discovered by positron emission tomography/computed tomography imaging following a successful pregnancy.  97:713-715. 2005
  • Outcomes of Stage I/II vulvar cancer patients after negative superficial inguinal lymphadenectomy.  98:309-312. 2005
  • The impact of aborted radical hysterectomy in patients with cervical carcinoma.  95:204-207. 2004
  • Infectivity enhanced adenoviral-mediated mda-7/IL-24 gene therapy for ovarian carcinoma.  94:352-362. 2004
  • Primary lung large cell carcinoma metastatic to the vulva: A case report and review of the literature.  94:829-831. 2004
  • Radical hysterectomy and pelvic lymphadenectomy for stage IB2 cervical cancer.  93:429-434. 2004
  • The role of radical parametrectomy in the treatment of occult cervical carcinoma after extrafascial hysterectomy.  92:215-219. 2004
  • Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: A preliminary investigation.  89:233-235. 2003
  • Stage IC adenocarcinoma of the endometrium: Survival comparisons of surgically staged patients with and without adjuvant radiation therapy.  89:295-300. 2003
  • Complications of indwelling venous access devices in patients with gynecologic malignancies.  91:591-595. 2003
  • Uterine papillary serous carcinoma: Comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy.  91:470-475. 2003
  • A pilot study of ovarian cancer chemoprevention using medroxyprogesterone acetate in an avian model of spontaneous ovarian carcinogenesis.  87:57-63. 2002
  • Conservative management of Stage I endometrial carcinoma after surgical staging.  84:194-200. 2002
  • Treatment preferences in recurrent ovarian cancer.  86:200-211. 2002
  • A noninvasive reporter system to image adenoviral-mediated gene transfer to ovarian cancer xenografts.  83:432-438. 2001
  • An immunomagnetic-based method for the purification of ovarian cancer cells from patient-derived ascites.  82:57-63. 2001
  • Bax-induced apoptosis as a novel gene therapy approach for carcinoma of the cervix.  83:370-377. 2001
  • Genetic origin of malignant trophoblastic neoplasms analyzed by sequence tag site polymorphic markers.  81:247-253. 2001
  • Immunohistochemical expression of molecular markers in an avian model: A potential model for preclinical evaluation of agents for ovarian cancer chemoprevention.  81:373-379. 2001
  • Predictors of outcome in small cell carcinoma of the cervix - A case series.  83:216-220. 2001
  • Transcriptional targeting for ovarian cancer gene therapy.  82:229-237. 2001
  • A patient presenting with a pelvic mass, elevated CA-125, and fever.  77:471-472. 2000
  • An advanced generation of adenoviral vectors selectively enhances gene transfer for ovarian cancer gene therapy approaches.  74:227-234. 1999
  • High-efficacy thymidine kinase gene transfer to ovarian cancer cell lines mediated by herpes simplex virus type I vector.  71:278-287. 1998
  • An umbilical metastasis after laparoscopy for squamous cell carcinoma of the cervix.  64:507-509. 1997
  • Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu- CC49: A phase I/II study.  65:94-101. 1997
  • Transductional efficacy and safety of an intraperitoneally delivered adenovirus encoding an anti-erbB-2 intracellular single-chain antibody for ovarian cancer gene therapy.  64:378-385. 1997
  • Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbb-2 single-chain antibody.  59:8-14. 1995
  • Intracranial metastases from carcinoma cervix and review of literature.  46:391-392. 1992
  • Coexisting intraductal breast carcinoma and metastatic choriocarcinoma presenting as a breast mass.  43:295-299. 1991
  • Establishment and characterization of a human cell line from a serous papillary endometrial carcinoma.  33:301-312. 1989
  • Intraperitoneal chromic phosphate in ovarian cancer: Risks and benefits.  32:314-318. 1989
  • Endometrial stromal cells in culture: An attempt to understand the genesis and biologic activity of uterine sarcomas.  24:247-257. 1986
  • Genital aerobic bacterial flora of women receiving radiotherapy for gynecologic malignancy.  23:35-39. 1986
  • An extra-adrenal pheochromocytoma mimicking lymph node metastasis from a cervical cancer.  13:416-422. 1982
  • International Standard Serial Number (issn)

  • 0090-8258
  • Electronic International Standard Serial Number (eissn)

  • 1095-6859